Magnetic Resonance Imaging of Liver Metastases: Experimental Comparison of Anionic and Conventional Superparamagnetic Iron Oxide Particles With a Hepatobiliary Contrast Medium During Dynamic and Uptake Phases
- 1 July 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Investigative Radiology
- Vol. 43 (7), 496-503
- https://doi.org/10.1097/rli.0b013e31816f1be1
Abstract
To assess the contrast-enhancing effects of citrate-coated superparamagnetic iron oxide particles (VSOP-C184) in a rat liver tumor model using dynamic and delayed magnetic resonance imaging in comparison to carboxydextran-coated particles (ferucarbotran) and a hepatobiliary contrast medium (gadobenate dimeglumine). A total of 32 male rats with liver tumors (CC-531 colorectal carcinoma) were examined at 1.5 T with a T1-weighted dynamic series (3D gradient echo sequence) and T1-weighted and T2*-weighted images (2D gradient echo sequences) before and 15 and 90 minutes after injection. VSOP-C184 was investigated at doses of 0.015, 0.045, and 0.06 mmol Fe/kg, ferucarbotran at 0.015 mmol Fe/kg, and gadobenate dimeglumine at 0.025, 0.05, and 0.1 mmol Gd/kg. Liver-tumor contrast-to-noise ratio (CNR) was calculated and statistically compared. T1-weighted dynamic images: VSOP-C184 has significantly higher CNR values at a dose of 0,015 mmol Fe/kg than ferucarbotran at the same dose (P = 0.001). VSOP-C184 produces a significantly higher CNR at a dose of 0.045 mmol Fe/kg than gadobenate dimeglumine at a dose of 0.05 mmol Gd/kg (P = 0.019). At a dose of 0.06 mmol Fe/kg, the CNR for VSOP-C184 is significantly lower than that of gadobenate dimeglumine (0.1 mmol Gd/kg) (P = 0.005).T2-weighted delayed images: CNR values of VSOP-C184 are similar to those of ferucarbotran and are significantly higher than those of gadobenate dimeglumine (P < 0.05). On T1-weighted magnetic resonance imaging of liver tumors VSOP-C184 produces a high contrast comparable to that of a hepatobiliary contrast medium in addition to its contrast-enhancing effect in T2-weighted imaging.Keywords
This publication has 31 references indexed in Scilit:
- Focal nodular hyperplasia: Lesion characteristics on state‐of‐the‐art MRI including dynamic gadolinium‐enhanced and superparamagnetic iron‐oxide‐uptake sequences in a prospective studyJournal of Magnetic Resonance Imaging, 2006
- Focal Liver Lesions: SPIO-, Gadolinium-, and Ferucarbotran-enhanced Dynamic T1-weighted and Delayed T2-weighted MR Imaging in RabbitsRadiology, 2006
- Comparison of Gadolinium-BOPTA and Ferucarbotran-Enhanced Three-Dimensional T1-Weighted Dynamic Liver Magnetic Resonance Imaging in the Same PatientInvestigative Radiology, 2006
- Phase I Clinical Evaluation of Citrate-coated Monocrystalline Very Small Superparamagnetic Iron Oxide Particles as a New Contrast Medium for Magnetic Resonance ImagingInvestigative Radiology, 2004
- Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applicationsEuropean Radiology, 2003
- MR imaging of liver tumorsRadiologic Clinics of North America, 2003
- Monomer-Coated Very Small Superparamagnetic Iron Oxide Particles as Contrast Medium for Magnetic Resonance ImagingInvestigative Radiology, 2002
- Detection of focal hepatic lesions: Comparison of unenhanced and SHU 555 A-enhanced MR imaging versus biphasic helical CTAPJournal of Magnetic Resonance Imaging, 2000
- RES-specific imaging of the liver and spleen with iron oxide particles designed for blood pool MR-angiographyJournal of Magnetic Resonance Imaging, 1999
- Detection of hepatic metastases: ferumoxides-enhanced MR imaging versus unenhanced MR imaging and CT during arterial portography.Radiology, 1996